前列地尔治疗冠状动脉粥样硬化性心脏病患者的临床效果

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (32 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the clinical effect of Alprostadil in the treatment of patients with coronary atherosclerotic heart disease. Methods Fifty patients with coronary atherosclerotic heart disease treated in our hospital from October 2016 to October 2018 were selected as the research subjects, they were divided into the observation group (25 cases) and the control group (25 cases) according to the random number table method. The observation group was treated with Alprostadil, the control group was treated with Nitroglycerin. The clinical treatment effects, cardiac function-related indicators, and blood lipid levels before and after treatment were compared between the two groups. Results The total effective rate of treatment in the observation group was higher than that in the control group, the difference was statistically significant (P＜0.05). The cardiac output (SV) of the observation group was higher than that of the control group, the heart rate (HR) was lower than that of the control group, the differences were statistically significant(P＜0.05). Before treatment, there were no significant differences in serum total cholesterol (TC), triacylglycerol (TG),low density lipoprotein cholesterol (LDL-C), and high density lipoprotein cholesterol (HDL-C) between the two groups(P＞0.05). After treatment, the levels of TC, TG, and LDL-C in the two groups were lower than those of before treatment, the levels of HDL-C was higher than that of before treatment, the levels of TC, TG, LDL-C in the observation group were lower than those in the control group, the levels of HDL-C was higher than that in the control group, the differences were statistically significant (P ＜0.05). Conclusion The use of Alprostadil in patients with coronary atherosclerotic heart disease can improve the treatment effect, improve cardiac function indicators and blood lipid levels, which is worthy of clinical application.

Key words： Alprostadil Coronary atherosclerotic heart disease Clinical effect Cardiac function

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I6/76

[1]	李梓锋.不同他汀药物治疗早发冠状动脉粥样硬化性心脏病急性心肌梗死患者的近期效果[J].中国药物经济学，2018，9（4）：110-111.
[2]	熊劲.前列地尔对急性脑梗死患者纤维蛋白原及超敏C反应蛋白水平的影响[J].中国老年学杂志，2015，35（7）：1735-1737.
[3]	安英男.前列地尔对兔内皮细胞缺氧复氧损伤后抗栓功能的影响[J].中国药学杂志，2011，46（2）：105-108.
[4]	赵庆丰.前列地尔用于急性心肌梗死PCI 术后的效果观察[J].临床合理用药杂志，2015，8（34）：42-43.
[5]	杨薪.前列地尔对慢性心衰大鼠心肌基质金属蛋白酶表达及纤维化的影响[J].中国动脉硬化杂志，2018，23（3）：266-270.
[6]	熊劲，江显萍.前列地尔对急性脑梗死患者纤维蛋白原及超敏C 反应蛋白水平的影响[J].中国老年学杂志，2018，35（7）：1735-1737.
[7]	Krcutz RP，Nystrom P，Krcutz Y，et al.Inhibition of platclct agagrcgation by prostaglandin EL in diabctic paticnts during therapy with elopdogrel and aspirin [J].Platelets，2013，24（2）：145-150.
[8]	张榕华.不同剂量瑞舒伐他汀治疗冠状动脉粥样硬化效果对比及对病症的影响[J].中国当代医药，2016，10（18）：218-219.
[9]	Ye Z，Lu H，Guo W，et a l.The effect of alprostadilon preventing contrast -induced nephropathy for pereutancous coronary intervention in diabetic patients：a systematic review and meta-analysis[J].Medicine，2016，95（46）：5306.
[10]	吴君，邓根群.前列地尔对高危患者冠脉介入术后对比剂肾病的影响[J].中国当代医药，2018，11（8）：62-63.
[11]	王雪莲，郭新贵.高龄急性冠脉综合征患者治疗的相关问题[J].老年医学与保健，2015，21（3）：191-193.
[12]	徐帅，赵翠萍.经皮冠状动脉介入术后相关心肌损伤及前列地尔在其治疗中的研究进展[J].中华老年多器官疾病杂志，2017，16（6）：473-476.
[13]	王其新.冠状动脉粥样硬化性心脏病介入治疗回顾与展望[J].实用老年医学，2015，29（1）：3-5.
[14]	赵庆丰.前列地尔用于急性心肌梗死PCI 术后的效果观察[J].临床合理用药杂志，2015，8（34）：42-43.
[15]	赫明萍，马潇泓.前列地尔在冠状动脉粥样硬化性心脏病治疗中的应用[J].老年医学与保健，2017，23（5）：444-445.